Clinical trials: Onchocerciasis
Loiasis
A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
The aim of the study is to evaluate the safety and efficacy of a 3- and 5-day course of levamisole (2.5 mg/kg) in management of loiasis microfilaremia.
- Trial name
- STOP-FiLAR (NCT06252961)
- Testing
- Levamisole 3 days, Levamisole 5 days
- Where
- 2 sites in Republic of the Congo
- Volunteers
- 99 people
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Onchocerciasis
IVM Alone vs ALB + IVM Against Onchocerciasis
Onchocerciasis is a vector-borne nematode parasitic disease that causes severe disability. Onchocerciasis affects approximately 33 million people, mostly in 30 countries in sub-Saharan Africa (with small foci in Latin America and…
- Trial name
- NCT03238131
- Testing
- Ivermectin, Albendazole
- Where
- Ghana
- Volunteers
- 272 people
- Sponsor
- University Hospitals Cleveland Medical Center
Lymphatic Filariasis, Onchocerciasis
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Approximately 5,200 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas.
- Conditions
- Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections
- Trial name
- DOLF-LIBERIA (NCT01905436)
- Testing
- Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
- Where
- Liberia
- Volunteers
- 21,862 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Skin and Connective Tissue Diseases, Neglected Tropical Diseases
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited.
- Conditions
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy, Buruli Ulcer
- Trial name
- SkincAIr (NCT07506967)
- Testing
- A mobile app with AI functionality for diagnosing skin-related NTDs
- Where
- 5 sites in Democratic Republic of the Congo, Ethiopia and 3 more
- Volunteers
- 2,420 people
- Sponsor
- Kenya Medical Research Institute
Lymphatic Filariasis, Soil Transmitted Helminth Infections
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Approximately 3,500 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis endemic areas. The study will be performed in Indonesia in B. timori and W.
- Trial name
- DOLF-Indo (NCT01905423)
- Testing
- Albendazole (annual), Diethylcarbamazine (annual), Albendazole (semiannual)
- Where
- Indonesia
- Volunteers
- 17,108 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphatic Filariases, Onchocerciasis
Prevalence of LF Infection in Districts Not Included in LF Control Activities
Lymphatic filariasis is a neglected tropical disease earmarked for elimination as a public health problem by the year 2020. Since the year 2000, the Global Program for the Elimination of LF has together with endemic countries…
- Trial name
- NCT03131401
- Testing
- Diagnosis of lymphatic filariasis, Diagnosis of lymphatic Filariasis and onchocerciasis, DEC Patch
- Where
- Ghana
- Volunteers
- 3,736 people
- Sponsor
- Noguchi Memorial Institute for Medical Research
Onchocerciasis
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in…
- Trial name
- NCT04311671
- Testing
- Moxidectin, Ivermectin, Albendazole
- Where
- 2 sites in Côte d’Ivoire, Democratic Republic of the Congo
- Volunteers
- 12,979 people, healthy volunteers welcome
- Sponsor
- Medicines Development for Global Health
Healthy Volunteers
First in Man Clinical Trial of Emodepside (BAY 44-4400)
This study will investigate the safety, tolerability, and pharmacokinetics of single ascending doses of emodepside (BAY 44-4400) in healthy male volunteers.
- Trial name
- NCT02661178
- Testing
- emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Onchocerciasis
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes river blindness.
- Trial name
- NCT00790998
- Testing
- Moxidectin, Ivermectin
- Where
- 4 sites in Democratic Republic of the Congo, Ghana and 1 more
- Volunteers
- 1,497 people
- Sponsor
- Medicines Development for Global Health
Leprosy, Lymphatic Filariases
Integrating Mental Health Into Neglected Tropical Disease Care in Ghana
Background Neglected Tropical Diseases (NTDs) are a group of diseases that are more common among the poorest people in the poorest countries.
- Conditions
- Leprosy, Lymphatic Filariases, Buruli Ulcer, Onchocerciasis
- Trial name
- IMAGINE (NCT07248462)
- Testing
- WHO Essential Care package for mental health and NTDs
- Volunteers
- 200 people
- Sponsor
- Liverpool School of Tropical Medicine
Ivermectin, Onchocerciasis
Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
Many studies have reported an association between epilepsy, including Nodding Syndrome (NS), and onchocerciasis (river blindness).
- Conditions
- Ivermectin, Onchocerciasis, Epilepsy
- Trial name
- OAETREAT (NCT03052998)
- Testing
- Ivermectin
- Where
- Democratic Republic of the Congo
- Volunteers
- 91 people
- Sponsor
- Robert Colebunders
Onchocerciasis, Loiasis
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Onchocerciasis, also known as river blindness, is one of the disease targeted for elimination by the World Health Organization (WHO) in the group of Neglected Tropical Diseases.
- Conditions
- Onchocerciasis, Loiasis, Mansonelliasis, Healthy Volunteers
- Trial name
- Obi1 (NCT06350851)
- Testing
- Biological samples collection (blood drawing + feces)
- Where
- Cameroon
- Volunteers
- 1,128 people, healthy volunteers welcome
- Sponsor
- Bioaster
Onchocerciasis
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
The DOLF Ocular Changes after Ivermectin study will investigate the kinetics of O. volvulus microfilaria (Mf) in the eye following treatment with ivermectin.
- Trial name
- NCT03517462
- Testing
- Ivermectin 3Mg Tab
- Where
- Ghana
- Volunteers
- 231 people
- Sponsor
- Washington University School of Medicine
Onchocercal Subcutaneous Nodule, Epilepsy
Onchocerciasis-Associated Epilepsy, an Explorative Case-control Study
This is an exploratory case control study with the aim to compare the Onchocerca volvulus virome between persons with onchocerciasis-associated epilepsy (OAE) and persons with onchocerciasis but without epilepsy.
- Conditions
- Onchocercal Subcutaneous Nodule, Epilepsy, Virus
- Trial name
- NCT05868551
- Testing
- nodulectomy
- Where
- South Sudan
- Volunteers
- 40 people
- Sponsor
- Universiteit Antwerpen
Filariasis, Lymphatic, Onchocerciasis
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
Lymphatic filariasis and onchocerciasis are a group of neglected tropical diseases caused by the transmission of worm larvae (microfilaria) by biting insects.
- Trial name
- AWOL (NCT05084560)
- Testing
- AWZ1066S
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Onchocerciasis
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).
- Trial name
- NCT00127504
- Testing
- Rifampin, Azithromycin
- Where
- Guatemala
- Volunteers
- 80 people
- Sponsor
- Centers for Disease Control and Prevention
Lymphatic Filariasis, Onchocerciasis
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
Approximately 4,000 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas.
- Conditions
- Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections
- Trial name
- NCT02032043
- Testing
- Annual versus Semiannual Albendazole plus Ivermectin MDA
- Where
- Côte d’Ivoire
- Volunteers
- 14,457 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis, Ascaris Lumbricoides Infection
Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
This clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in…
- Conditions
- Onchocerciasis, Ascaris Lumbricoides Infection, Trichuris Trichiura; Infection, Hookworm Infections
- Trial name
- EKAIO (NCT07145736)
- Testing
- Moxidectin, Ivermectin
- Where
- Angola
- Volunteers
- 52,000 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Onchocerciasis
Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
The primary purpose of this study was to determine the safety and tolerability of moxidectin in subjects infected with Onchocerca volvulus (a parasitic worm).
- Trial name
- NCT00300768
- Testing
- 2 mg moxidectin, ivermectin 150 mcg/kg, 4 mg moxidectin
- Where
- Ghana
- Volunteers
- 172 people
- Sponsor
- Medicines Development for Global Health
Loiasis With Positive Blood Microfilaremia, Loiasis
21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia
Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.
- Trial name
- STOP-FiLAR-ALB (NCT06613997)
- Testing
- Albendazole 400mg
- Volunteers
- 100 people
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo